Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

An analysis reveals a spike in pro-Russian disinformation networks surrounding the attempt to oust the European Commission ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

AstraZeneca, Pfizer and other multinational drug companies have spent a record amount on medicines developed by Chinese biotechs this year, underscoring how Big Pharma is increasingly reliant on China ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

Dividned stocks: 15 small-cap stocks have given dividends of up to ₹200 in the last 12 months, resulting in a dividend yield ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...